Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.

RobCo CEO Roman Hölzl Talks $1 Billion Unicorn Valuation
07:43

US Attorney General Todd Blanche Talks Election Fraud Cases
17:08

Senior Fellow at Council on Foreign Relations Rebecca Patterson Talks "Too Much"
07:54